Clinical medicine

Vyriad to Build State-of-the-Art Facility for Manufacturing Oncolytic Virus Anti-Cancer Vaccines in Rochester, Minn.

Retrieved on: 
Thursday, May 10, 2018
Biotechnology, Experimental cancer treatments, Virotherapy, Oncolytic virus, Medicine, Biology, Vesicular stomatitis virus, Clinical medicine, Virus, Adenoviridae, Oncolytic adenovirus, Akseli Hemminki

The building plans include offices, research laboratories, and a state-of-the-art Good Manufacturing Practice (GMP) facility for production of the company's clinical-stage oncolytic virus therapies that are in development for the treatment of various cancers.

Key Points: 
  • The building plans include offices, research laboratories, and a state-of-the-art Good Manufacturing Practice (GMP) facility for production of the company's clinical-stage oncolytic virus therapies that are in development for the treatment of various cancers.
  • The new manufacturing facility will enable production, quality-control testing, and supply of clinical-grade oncolytic virus therapies for later-stage clinical studies.
  • Vyriad is a clinical-stage biotechnology company developing novel oncolytic virus therapies for the treatment of cancers that have significant unmet need.
  • Vyriad's oncolytic immunovirotherapy products are based on the company's engineered Oncolytic Vesicular Stomatitis Virus (VSV) and Oncolytic Measles Virus platforms that enable selective destruction of cancer cells without harming normal tissues.

ReShape Lifesciences Announces Submission for Approval of ReShape Balloon™ in Canada

Retrieved on: 
Thursday, May 10, 2018
Medicine, Bariatrics, Surgery, Clinical medicine, Obesity, Amphetamine, Body shape, Nutrition, Weight loss, Bariatric surgery, Gastric balloon

Canada has been estimated to have the seventh highest obesity rate amongst developed countries, with just under 30% of the adult population being obese, according to a 2017 report published by OECD Health Statistics.

Key Points: 
  • Canada has been estimated to have the seventh highest obesity rate amongst developed countries, with just under 30% of the adult population being obese, according to a 2017 report published by OECD Health Statistics.
  • ReShape Lifesciences is a medical device company focused on technologies to treat obesity and metabolic diseases.
  • The FDA-approved ReShape Balloon System involves a non-surgical weight loss procedure that uses advanced balloon technology designed to take up room in the stomach to help people with a 30-40 kg/m2 Body Mass Index (BMI) and at least one co-morbidity lose weight.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

After Losing 160 Pounds, Middle-Aged Woman Becomes Marathoner

Retrieved on: 
Thursday, May 10, 2018
Medicine, Clinical medicine, RTT, Surgery, Diabetes mellitus, Insulin, Sleep apnea, Apnea, Bariatric surgery, Bariatrics, Bearden

After losing 160 pounds, now she runs marathons.

Key Points: 
  • After losing 160 pounds, now she runs marathons.
  • Click here to watch an inspiring video of Bearden, or download a bariatric surgery guide.
  • "I ended up in the hospital," said Bearden, a former insulin-dependent diabetic with high blood pressure and sleep apnea.
  • In the process of losing 160 pounds, she wanted to get in better physical shape.

Searchlight Pharma Announces Launch of Bulkamid® for Treatment of Female Stress Urinary Incontinence

Retrieved on: 
Thursday, May 10, 2018
Medicine, Urinary incontinence, Surgery, Clinical medicine, Stress incontinence, Gel, Sling, Sui, Incontinence, Continence

MONTREAL, May 10, 2018 /CNW Telbec/ -Searchlight Pharma, a Canadian specialty pharmaceutical company committed to improving life-long human health and wellness, today announced the launch of commercial activities for Bulkamidfor the treatment of female stress urinary incontinence ("SUI").Bulkamid which is manufactured by Contura International, and distributed and promoted bySearchlight Pharma, is available nationwide inCanada.

Key Points: 
  • MONTREAL, May 10, 2018 /CNW Telbec/ -Searchlight Pharma, a Canadian specialty pharmaceutical company committed to improving life-long human health and wellness, today announced the launch of commercial activities for Bulkamidfor the treatment of female stress urinary incontinence ("SUI").Bulkamid which is manufactured by Contura International, and distributed and promoted bySearchlight Pharma, is available nationwide inCanada.
  • "Bulkamid provides Canadian women with an effective and safe treatment alternative to surgical procedures that involve tapes, slings and meshes.
  • Bulkamidis a homogenous hydrophilic hydrogel used in the treatment of female stress urinary incontinence.
  • 2 Sokol ER, Karram MM, Dmochowski R. Efficacy and safety of polyacrylamide hydrogel for the treatment of female stress incontinence: a randomized, prospective, multicenter North American study.

Intracranial Pressure Monitors Market to Represent Swift Progress Owing to Enhanced Acceptance of EVD: Radiant Insights, Inc.

Retrieved on: 
Thursday, May 10, 2018
Medicine, Neurochemistry, Clinical medicine, Neurotrauma, Medical signs, Anesthesia, Computer monitor, Intracranial pressure, Monitoring, Ketamine, ICP

Causes for example stringent rules from the healthcare and medicinal administrations and the progress of non-intrusive Intracranial Pressure Monitors [ICP] and wireless Intracranial Pressure Monitors [ICP] monitoring arrangements will also add to the progress of this market in the years to come.

Key Points: 
  • Causes for example stringent rules from the healthcare and medicinal administrations and the progress of non-intrusive Intracranial Pressure Monitors [ICP] and wireless Intracranial Pressure Monitors [ICP] monitoring arrangements will also add to the progress of this market in the years to come.
  • The international Intracranial Pressure Monitors Market is divided by Type of Product, Type of Technology, and the Area.
  • The division of the international Intracranial Pressure Monitors Market on the source of Type of Product extends Transducers, Monitors, and Consumables.
  • Access 101 page research report with TOC on "Intracranial Pressure Monitors Market" available with Radiant Insights, Inc. @ https://www.radiantinsights.com/research/global-intracranial-pressure-mo...
    The division of the international Intracranial Pressure Monitors Market on the source of Area extends North America, Europe, Asia-Pacific, Middle East & Africa, and South America.

Protagonist Therapeutics Reports First Quarter 2018 Financial Results

Retrieved on: 
Wednesday, May 9, 2018
Medicine, Hematology, Hepatology, Hepcidin, Iron metabolism, Anatomy, Thalassemia, Beta thalassemia, Cash and cash equivalents, Clinical medicine

NEWARK, Calif., May 9, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported its financial results for the first quarter ended March 31, 2018.

Key Points: 
  • NEWARK, Calif., May 9, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported its financial results for the first quarter ended March 31, 2018.
  • With our hepcidin mimetic PTG-300, we plan to commence a Phase 2 study in beta-thalassemia patients in the fourth quarter of 2018."
  • Protagonist reported a net loss of$7.7millionfor the first quarter of 2018, as compared to a net loss of$14.1 millionfor the same period of 2017.
  • Protagonist ended the first quarter of 2018 with$140.5 millionin cash, cash equivalents and investments.

Global Molecular Diagnostics Research Report 2018 with Profiles of 296 Companies - Forecast to 2027

Retrieved on: 
Wednesday, May 9, 2018
Biotechnology, Biology, Molecular diagnostics, Medicine, Clinical medicine

DUBLIN, May 9, 2018 /PRNewswire/ -- The "Molecular Diagnostics - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 9, 2018 /PRNewswire/ -- The "Molecular Diagnostics - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • Initial applications of molecular diagnostics were mostly for infections but are now increasing in the areas of genetic disorders, preimplantation screening and cancer.
  • The number of companies involved in molecular diagnostics has increased remarkably during the past few years.
  • More than 1,000 companies have been identified to be involved in developing molecular diagnostics and 296 of these are profiled in the report along with tabulation of 658 collaborations.

Quebec Government makes NARCAN™ Nasal Spray free to anyone 14 years or older through Free naloxone program

Retrieved on: 
Wednesday, May 9, 2018
Medicine, Chemistry, Clinical medicine, RTT, Morphinans, Alcohols, Antidotes, Naloxone, Nasal spray, Opioid overdose, Bertha Madras

Adapt Pharma's NARCAN (naloxone) Nasal Spray 4mg will now be accessible free of charge to all Quebec residents 14 years or older through local pharmacies, effective May 9 2018.

Key Points: 
  • Adapt Pharma's NARCAN (naloxone) Nasal Spray 4mg will now be accessible free of charge to all Quebec residents 14 years or older through local pharmacies, effective May 9 2018.
  • NARCAN Nasal Spray 4mg is the highest concentrated dose of naloxone currently available and is a needle-free nasal spray formulation of naloxone used for the emergency treatment of a known or suspected opioid overdose.
  • Pharmacies will be able to obtain NARCAN Nasal Spray from their regular distributors, and NARCAN Nasal Spray is available at major wholesalers in the Quebec market.
  • The full product monograph for NARCAN Nasal Spray is available at http://www.narcan.com/pdf/NARCAN-Prescribing-Information.pdf
    Adapt Pharma Canada Ltd. has established dedicated distribution channels that allow first responders, public health organizations, and individuals to readily access NARCAN Nasal Spray.

Baker and 8 Other Leading Cannabis Companies Launch the "Future of Cannabis Retail" Movement to Help the Industry Evolve and Operate as a Collaborative Ecosystem

Retrieved on: 
Wednesday, May 9, 2018
Medicinal plants, Herbalism, Medicine, Entheogens, Euphoriants, Health, Clinical medicine, Cannabis industry, Cannabis, Legality of cannabis, Medical cannabis

"We want to bring together consumers, dispensaries, ancillary services, cultivators, and producers to take the cannabis industry further than any other industry," said Joel Milton, CEO of Baker.

Key Points: 
  • "We want to bring together consumers, dispensaries, ancillary services, cultivators, and producers to take the cannabis industry further than any other industry," said Joel Milton, CEO of Baker.
  • "We have the opportunity to transform cannabis retail and cultivate an industry that operates as a collaborative ecosystem.
  • Using motion graphics, it highlights data transparency among other things and how it can impact all facets of the cannabis industry from seed to cannabis retail.
  • Baker is the leading CRM for the cannabis industry, servicing more than 1,000 dispensaries across the US and Canada.

Medi-Tate's Minimally Invasive TIND System for Enlarged Prostate Now Shown to be Durable Through Three Years: Results From Pilot Study

Retrieved on: 
Wednesday, May 9, 2018
Medicine, Clinical medicine, Anatomy, RTT, Andrology, Benign prostatic hyperplasia, Men's Health, Lower urinary tract symptoms, Prostate, BPH, Transurethral microwave thermotherapy, Aquablation therapy

The study evaluated the safety and effectiveness of the TIND, the company's prototype for the novel iTind System, developed as a treatment for patients with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), or enlarged prostate.

Key Points: 
  • The study evaluated the safety and effectiveness of the TIND, the company's prototype for the novel iTind System, developed as a treatment for patients with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), or enlarged prostate.
  • "The TIND, now iTind, is unique in that it is a device that performs a procedure.
  • The CE Marked iTind System is a minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).
  • The iTind, temporarily implanted nitinol cutting device, is implanted through a straightforward, minimally invasive transurethral procedure and left in place for only 5 to 7 days.